Edition:
United States

Vical Inc (VICL.A)

VICL.A on American Stock Exchange

1.48USD
23 Feb 2018
Change (% chg)

$0.02 (+1.37%)
Prev Close
$1.46
Open
--
Day's High
$1.48
Day's Low
$1.48
Volume
0
Avg. Vol
70
52-wk High
$2.97
52-wk Low
$1.40

Latest Key Developments (Source: Significant Developments)

Astellas Says Cytomegalovirus Vaccine (ASP0113) Did Not Meet Its Primary Or Secondary Endpoints In Phase 3 Helios Clinical Trial​
Monday, 22 Jan 2018 03:00am EST 

Jan 22 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS AND VICAL ANNOUNCE TOP-LINE RESULTS FOR PHASE 3 TRIAL OF CYTOMEGALOVIRUS VACCINE ASP0113 IN HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS.ASTELLAS PHARMA INC SAYS ‍VACCINE WAS GENERALLY WELL TOLERATED, WITH INJECTION-SITE REACTIONS BEING MOST COMMONLY REPORTED ADVERSE EVENT​.ASTELLAS PHARMA - ASP0113 DID NOT MEET ITS PRIMARY OR SECONDARY ENDPOINTS IN PHASE 3 HELIOS CLINICAL TRIAL​.  Full Article

‍Stonepine Capital Management reports 6.6 pct passive stake in Vical
Wednesday, 15 Nov 2017 06:12am EST 

Nov 15 (Reuters) - Vical Inc :‍Stonepine Capital Management Llc reports 6.6 percent passive stake in Vical Inc as on November 8, 2017 - SEC filing​.  Full Article

Vical Incorporated announces pricing of $25 mln underwritten public offering of common stock
Wednesday, 8 Nov 2017 06:30am EST 

Nov 8 (Reuters) - Vical Inc :Vical Incorporated announces pricing of $25 million underwritten public offering of common stock.Says public offering of 14.3 million common shares priced at $1.75per share.  Full Article

VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON TREATMENT FOR CHRONIC HEPATITIS B INFECTION
Tuesday, 24 Oct 2017 06:30am EDT 

Oct 24 (Reuters) - Vical Inc ::VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON A TREATMENT FOR CHRONIC HEPATITIS B INFECTION.‍INITIAL STAGE OF PROGRAM WILL BE TO DEMONSTRATE PRECLINICAL PROOF OF CONCEPT FOR INHIBITING HBV INFECTION IN HUMAN LIVER MODEL IN H2 2018​.‍ANGES HAS PROVIDED PARTIAL FUNDING FOR INITIAL STAGE OF PROGRAM​.‍IF INITIAL STAGE OF PROGRAM IS SUCCESSFUL, VICAL EXPECTS THAT ANGES WILL CONTINUE TO PARTICIPATE IN FUNDING OF PROGRAM ​.‍ANGES GRANTED RIGHT OF FIRST REFUSAL TO NEGOTIATE WITH CO FOR EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE HEPATITIS B THERAPY IN JAPAN​.  Full Article

Vical reports Q3 loss per share $0.27
Monday, 23 Oct 2017 06:30am EDT 

Oct 23 (Reuters) - Vical Inc :Vical reports third quarter 2017 financial and operational results.Q3 loss per share $0.27.Q3 revenue $3.2 million versus $2.6 million.  Full Article

Vical Inc files for common stock offering of up to $23.0 mln
Monday, 16 Oct 2017 05:00pm EDT 

Oct 16 (Reuters) - Vical Inc :Vical Inc files for common stock offering of up to $23.0 million - SEC filing‍​.  Full Article

Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial
Tuesday, 10 Oct 2017 06:30am EDT 

Oct 10 (Reuters) - Vical Inc :Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial.Vical Inc - ‍Astellas Pharma Inc. expects top-line data to be available in Q1 of 2018​.Vical Inc - continues to provide Astellas with development, regulatory and manufacturing support for program​.  Full Article

Vical announces that its antifungal VL-2397 is eligible for limited use indication approval by FDA
Monday, 2 Oct 2017 04:15pm EDT 

Oct 2 (Reuters) - Vical Inc :Vical announces that its antifungal VL-2397 is eligible for limited use indication approval by FDA based on a single phase 2 efficacy trial.Vical Inc - ‍plans to initiate phase 2 trial of VL-2397 for treatment of invasive Aspergillosis in 4Q 2017​.  Full Article

Vical Inc Q2 loss per share $0.30
Tuesday, 8 Aug 2017 06:30am EDT 

Aug 8 (Reuters) - Vical Inc :Vical reports second quarter 2017 financial and operational results.Q2 loss per share $0.30.Q2 revenue $3.4 million versus $4.1 million.  Full Article

Vical Inc names Anthony Ramos CFO
Thursday, 1 Jun 2017 06:58am EDT 

June 1 (Reuters) - Vical Inc :Vical Inc says on May 25, 2017, board appointed Anthony A. Ramos, company's chief accounting officer, to be company's chief financial officer.In the role as CFO, Ramos will also serve as co's principal financial officer, principal accounting officer, replacing Vijay B. Samant as co's CFO.  Full Article

BRIEF-Vical Announces Restructuring To Focus Resources On Hsv-2 And Antifungal Clinical Programs

* VICAL ANNOUNCES RESTRUCTURING TO FOCUS RESOURCES ON HSV-2 AND ANTIFUNGAL CLINICAL PROGRAMS